Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Dermatitis, Atopic
Interventions
DRUG

Dupilumab

Solution for injection, subcutaneous (SC)

DRUG

Matching placebo

Solution for injection, subcutaneous (SC)

Trial Locations (48)

10032

Regeneron Investigational Site, New York

14642

Regeneron Investigational Site, Rochester

19104

Regeneron Investigational Site, Philadelphia

20010

Regeneron Investigational Site, Washington D.C.

20850

Regeneron Investigational Site, Rockville

23502

Regeneron Investigational Site, Norfolk

24105

Regeneron Investigational Site, Kiel

29420

Regeneron Investigational Site, North Charleston

29425

Regeneron Investigational Site, Charleston

31217

Regeneron Investigational Site, Macon

31904

Regeneron Investigational Site, Columbus

33146

Regeneron Investigational Site, Coral Gables

35209

Regeneron Investigational Site, Birmingham

39328

Regeneron Investigational Site, Sandy Springs

48149

Regeneron Investigational site, Münster

48197

Regeneron Investigational Site, Ypsilanti

49074

Regeneron Investigational Site, Osnabrück

53226

Regeneron Investigational Site, Milwaukee

60590

Regeneron Investigational site, Frankfurt am Main

60611

Regeneron Investigational Site, Chicago

68505

Regeneron Investigational Site, Lincoln

78218

Regeneron Investigational Site, San Antonio

78723

Regeneron Investigational Site, Austin

80337

Regeneron Investigational Site, München

80802

Regeneron Investigational site, München

85234

Regeneron Investigational Site, Gilbert

90027

Regeneron Investigational site, Los Angeles

90274

Regeneron Investigational Site, Rolling Hills Estates

90808

Regeneron Investigational Site, Long Beach

92123

Regeneron Investigational Site, San Diego

94304

Regeneron Investigational Site, Palo Alto

97239

Regeneron Investigational Site, Portland

98105

Regeneron Investigational Site, Seattle

113756

Regeneron Investigational Site, Forest Hills

33612-3807

Regeneron Investigational Site, Tampa

02115

Regeneron Investigational Site, Boston

48109-5314

Regeneron Investigational Site, Ann Arbor

63104-1003

Regeneron Investigational Site, St Louis

07601

Regeneron Investigational Site, Hackensack

01307

Regeneron Investigational Site, Dresden

15-453

Regeneron Investigational Site, Bialystok

40-648

Regeneron Investigational Site, Katowice

31-011

Regeneron Investigational Site, Krakow

27-400

Regeneron Investigational Site, Ostrowiec Świętokrzyski

01-142

Regeneron Investigational Site, Warsaw

01-817

Regeneron Investigational Site, Warsaw

M13 9WL

Regeneron Investigational Site, Manchester

S10 2TH

Regeneron Investigational Site, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03346434 - Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | Biotech Hunter | Biotech Hunter